Shandong Buchang Pharmaceuticals Co.Ltd(603858) march 16 announced that its holding subsidiary Zhejiang Tianyuan’s product “tetravalent influenza virus split vaccine” has obtained the ethical review approval of the vaccine clinical trial ethics committee of Yunnan Center for Disease Control and prevention, and started the phase III clinical trial.
Tetravalent Influenza Split Vaccine is mainly used to stimulate the body’s immunity against influenza virus and prevent influenza caused by the strain. According to the data of Intranet, the amount of converted batch issuance of influenza virus split vaccine in China was 967 million yuan in 2019 and 983 million yuan in 2020.
Shandong Buchang Pharmaceuticals Co.Ltd(603858) said that the vaccine obtained the notice of approval of drug clinical trial in December 2020 and the ethical review approval of the vaccine clinical trial ethics committee of Yunnan Center for Disease Control and prevention in June 2021, and started the phase I / II clinical trial. As of February 28, 2022, the company has invested about 515573 million yuan in R & D expenses in the project.
